Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Ortho-McNeil-Janssen ends collaboration with Arena Pharma for APD-597 program

Nov. 5, 2010

Kowa claims new erythropoietin production enhancers

Nov. 5, 2010

Primary endpoint met in phase III HPN-100 trial in urea cycle disorders

Nov. 4, 2010

ENB-0040 shows promise to treat hypophosphatasia in children

Nov. 4, 2010

New neuropeptide Y5 receptor antagonists discovered

Nov. 3, 2010

FDA responds to Biodel regarding Linjeta NDA

Nov. 3, 2010

Novartis and Xenon Pharma claim new acyl-CoA desaturase inhibitors

Nov. 3, 2010

Protalix BioTherapeutics reports on taliglucerase alfa switchover trial

Nov. 3, 2010

New modulators of G protein-coupled receptors disclosed

Nov. 3, 2010

GSK and Amicus to develop Amigal for Fabry's disease

Nov. 2, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...